Kinda Recap of ASM | PTLA Message Board Posts

Portola Pharmaceuticals, Inc.

  PTLA website

PTLA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  6346 of 6521  at  6/16/2019 8:57:51 AM  by

erniewerner


 In response to msg 6345 by  seanleecfa
view thread

Re: Kinda Recap of ASM

 "Analysts have peak sales for Andexxa slated for 2025, but may actually be 2035 or even further out"
 
Biologics do have a much more effective moat than small molecules.  But for A to hold an essential long lived monopoly position assumes that future competition would only be from a biosimilar, essentially a generic version of A.  It is entirely possible that non-biologic could target the same indication.  We'll see.  
 
"2. I anticipate the PCC study to be insightful, but does anyone think this will change hearts and minds knowing that this is a study from a biased stakeholder?"
 
As long as the study design does not in some way unfairly favor the A treated patients, I believe the results will be considered a valid comparison.  Even though a study may be sponsored (funded) by an interested stakeholder, the actual studies are carried out by CRO's and institutions that have a larger vested interest in maintaining their reputation for impartiality than in a achieving specific trial outcome.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 8     Views: 574
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...